Modified Volumetric Modulated Arc Therapy in Left Sided Breast Cancer After Radical Mastectomy With Flattening Filter Free Versus Flattened Beams
Overview
Affiliations
Conventional volumetric modulated arc therapy (C-VMAT) for breast cancer after radical mastectomy had its limitation that resulted in larger volumes of normal tissue receiving low doses. We explored whether there was a way to deal with this disadvantage and determined the potential benefit of flattening filter-free (FFF) beams.Twenty patients with breast cancer after radical mastectomy were subjected to 3D conformal radiotherapy (3DCRT) and VMAT treatment planning. For VMAT plans, 3 different designs were employed with RapidArc form: conventional-VMAT plan (C-VMAT), modified-VMAT plan (M-VMAT), and modified-VMAT plan using FFF beams (M-VMAT-F). Plan quality and efficiency were assessed for all plans.For each technique in homogeneity, there were no statistically significant differences. VMAT plans showed superiority compared with 3DCRT in conformity. C-VMAT plans were obviously not only superior to 3DCRT in the medium to high-dose regions (about 15-50 Gy) but also resulted in larger volumes in low-dose regions (about 0-10 Gy). M-VMAT plans were similar to M-VMAT-F. Both of them might significantly reduce the regions of low dose compared with C-VMAT (V5lung: ∼ 11.5%; V5heart: ∼ 23.8%, P < 0.05), even less than 3DCRT in heart irradiation (V2.5heart, 9.4%, P < 0.05). For liver, contralateral breast, and lung irradiation, M-VMAT-F plans were slightly superior to M-VMAT with a reduction of ∼0.08, 0.2, and 0.24 Gy in the respective mean doses (P < 0.05).C-VMAT plans showed superiority compared with 3DCRT, while also resulted in larger volumes of normal tissue receiving low doses. M-VMAT and M-VMAT-F plans might not only reduce the region in the medium to high doses but also have lower volumes in low-dose regions. M-VMAT-F plans were slightly superior compared with M-VMAT due to further contralateral organs sparing.
Wu W, Yin H, Liu Z, Liu L, Xiao C, Xiao Y Front Oncol. 2024; 14:1418723.
PMID: 39640275 PMC: 11617583. DOI: 10.3389/fonc.2024.1418723.
Mishra S, Nanda S, Ahirwar M, Simran , M Rath S Cureus. 2023; 15(5):e38464.
PMID: 37276065 PMC: 10235212. DOI: 10.7759/cureus.38464.
He Y, Chen S, Gao X, Fu L, Kang Z, Liu J PLoS One. 2023; 18(1):e0280456.
PMID: 36693073 PMC: 9873183. DOI: 10.1371/journal.pone.0280456.
Adeneye S, Akpochafor M, Adedewe N, Habeebu M, Jubril R, Adebayo A Eur J Breast Health. 2023; 19(1):92-98.
PMID: 36605476 PMC: 9806941. DOI: 10.4274/ejbh.galenos.2022.2022-9-2.
Palani D, Govindaraj K, Sampathrajan S, Karunagaran L, Ganesh K Asian Pac J Cancer Prev. 2022; 23(12):4323-4332.
PMID: 36580016 PMC: 9971454. DOI: 10.31557/APJCP.2022.23.12.4323.